High Patient Interest in Cannabis for Parkinson’s, But Few Use ItPosted by On


There is high patient interest in medical cannabis to help alleviate motor and nonmotor symptoms of Parkinson’s disease (PD), yet few avail themselves of this treatment, new research shows.

In what investigators say is the largest “real world” survey of medical cannabis (MC) in this patient population, researchers in Germany found more than 50% were aware of MC for PD but less than 10% of PD patients used it. In addition, MC users reported significant reductions in motor and nonmotor symptoms PD symptoms including motor and nonmotor symptoms.

“Results suggests that MC might be helpful for selected PD patients with insufficient symptom relief despite their usual antiparkinsonian medication,” the researchers led by Carsten Buhmann, MD, head of the outpatient center for neurology at University Hospital Hamburg­–Eppendorf in Germany, write.

The study was published online November 11 in the Journal of Parkinson’s Disease.

Largest Survey To-Date

The increasing availability of MC in many countries has fueled interest in the drug’s potential ability to alleviate symptoms for many disorders. In Germany, cannabis has been legal since 2017 as a therapeutic option for patients with severe, treatment-resistant symptoms of PD.

However, the investigators note, little is known about PD patients’ view of…

Original Author Link click here to read complete story..

There is high patient interest in medical cannabis to help alleviate motor and nonmotor symptoms of Parkinson’s disease (PD), yet few avail themselves of this treatment, new research shows.

In what investigators say is the largest “real world” survey of medical cannabis (MC) in this patient population, researchers in Germany found more than 50% were aware of MC for PD but less than 10% of PD patients used it. In addition, MC users reported significant reductions in motor and nonmotor symptoms PD symptoms including motor and nonmotor symptoms.

“Results suggests that MC might be helpful for selected PD patients with insufficient symptom relief despite their usual antiparkinsonian medication,” the researchers led by Carsten Buhmann, MD, head of the outpatient center for neurology at University Hospital Hamburg­–Eppendorf in Germany, write.

The study was published online November 11 in the Journal of Parkinson’s Disease.

Largest Survey To-Date

The increasing availability of MC in many countries has fueled interest in the drug’s potential ability to alleviate symptoms for many disorders. In Germany, cannabis has been legal since 2017 as a therapeutic option for patients with severe, treatment-resistant symptoms of PD.

However, the investigators note, little is known about PD patients’ view of…



Source link

News

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.